ライフサイエンスコーパス: autonomic neuropathy

1 educed HRV identifies diabetic patients with autonomic neuropathy.

2 ood flow would be impaired in diabetics with autonomic neuropathy.

3 with long-standing diabetes and established autonomic neuropathy.

4 abetic distal symmetrical polyneuropathy and autonomic neuropathy.

5 evidence of definite and 10 (31%) had early autonomic neuropathy.

6 tential pathogenetic mechanisms for diabetic autonomic neuropathy.

7 31.3% Child B, and 60% Child C had definite autonomic neuropathy.

8 in patients with advanced liver disease and autonomic neuropathy.

9 eta as a new therapeutic target for diabetic autonomic neuropathy.

10 Half had autonomic neuropathy.

11 l dysautonomia (FD), a recessive sensory and autonomic neuropathy.

12 ulin treatment, metabolic abnormalities, and autonomic neuropathy.

13 nglionic antibody likely mediates autoimmune autonomic neuropathy.

14 tribute to the development of human diabetic autonomic neuropathy.

15 in the pathogenesis of experimental diabetic autonomic neuropathy.

16 arrhythmias associated with diabetic cardiac autonomic neuropathy.

17 s relatively spared in experimental diabetic autonomic neuropathy.

18 ibodies and had idiopathic or paraneoplastic autonomic neuropathy.

19 logic markers of various forms of autoimmune autonomic neuropathy.

20 iabetic large and small fiber peripheral and autonomic neuropathies.

21 Moreover, in hereditary sensory and autonomic neuropathies.

22 neuronal dysfunction and loss in the sensory/autonomic neuropathies.

23 nesis, pathophysiology and treatment of some autonomic neuropathies.

24 mmon signs were peripheral neuropathy (47%), autonomic neuropathy (31%), cerebellar ataxia (26%), sub

25 inating neuropathy (2.8; 1.6-5.1; P = .001), autonomic neuropathy (4.2; 1.4-12.3; P = .009), and mono

26 6 patients with idiopathic or paraneoplastic autonomic neuropathy (41 percent), in 6 of 67 patients w

27 ic gastrointestinal dysmotility, or diabetic autonomic neuropathy (9 percent), and in none of 44 pati

28 ients (13 female, 5 male) who had autoimmune autonomic neuropathy (AAN) and ganglionic acetylcholine

29 Autoimmune autonomic neuropathy (AAN) is an acquired, often severe,

30 There is evidence of an autonomic neuropathy affecting the lower-extremity blood

31 Sensory and autonomic neuropathy affects the majority of type II dia

32 Autonomic neuropathy (AN) is seen in both alcohol-induce

33 ave implications for both long-term diabetic autonomic neuropathies and insulin-induced hypoglycemia,

34 es patients with various forms of autoimmune autonomic neuropathy and distinguishes these disorders f

35 Diabetic autonomic neuropathy and endothelial dysfunction impair

36 ch could elucidate the link between diabetic autonomic neuropathy and stroke.

37 renal, or liver involvement or peripheral or autonomic neuropathy and treatment naive.

38 nerve abnormalities, frequent optic atrophy, autonomic neuropathy and upper and lower motor neurone s

39 axia, 2 Lambert-Eaton myasthenic syndrome, 1 autonomic neuropathy, and 1 motor neuropathy).

40 omia (FD) is a severe hereditary sensory and autonomic neuropathy, and all patients with FD have a sp

41 treatment of Parkinson's disease-associated autonomic neuropathy, and antioxidant therapies have bee

42 processes, including hepatitis C infection, autonomic neuropathy, and drug side effects, that can re

43 y aid in early detection of both sensory and autonomic neuropathy, and perhaps in the case of patient

44 The autonomic neuropathies are a group of disorders in which

45 Hereditary sensory and autonomic neuropathies are a group of phenotypically rel

46 The hereditary motor, sensory and autonomic neuropathies are a heterogeneous group of neur

47 Some autonomic neuropathies are treatable.

48 ion, axonal sensory-motor polyneuropathy and autonomic neuropathy are commonly seen in patients with

49 Cardiac autonomic neuropathy arises in the presence of uremia an

50 pathy, peripheral neuropathy, cardiovascular autonomic neuropathy, arterial stiffness, and hypertensi

51 Finally, autonomic neuropathy as a complication of severe liver d

52 s' CNFL correlated with the severity of both autonomic neuropathy assessed by the Compound Autonomic

53 In addition to the autonomic neuropathy associated with long-standing diabe

54 abetic distal symmetrical polyneuropathy and autonomic neuropathy but that the clinical role of ARIs

55 Autonomic neuropathies can also occur as a result of amy

56 rmine the association between cardiovascular autonomic neuropathy (CAN) and indices of left ventricle

57 y on the prevalence and incidence of cardiac autonomic neuropathy (CAN) in former DCCT intensive and

58 Cardiovascular autonomic neuropathy (CAN) is associated with increased

59 It has been suggested that cardiac autonomic neuropathy (CAN) might indicate those who are

60 myloidosis characterized by sensorimotor and autonomic neuropathy, cardiac conduction defects, and in

61 ly progressive gastrointestinal symptoms and autonomic neuropathy caused by autosomal dominant, hered

62 When evaluating a patient with subacute autonomic neuropathy, certain autoantibodies are importa

63 mmon member of a group of congenital sensory/autonomic neuropathies characterized by widespread senso

64 ary motor neuropathy, hereditary sensory and autonomic neuropathy, complicated hereditary spastic par

65 Diabetic autonomic neuropathy (DAN) has been invoked as a cause o

66 Diabetic autonomic neuropathy (DAN) may impact the BM, because th

67 The classical diabetic autonomic neuropathy (DAN) that eventually occurs in the

68 In subjects with diabetic autonomic neuropathy (DAN), distal left ventricular (LV)

69 d morbidity and mortality in severe diabetic autonomic neuropathy (DAN).

70 duals with long-standing type I diabetes and autonomic neuropathy has not been assessed, nor has it b

71 Hereditary sensory and autonomic neuropathies (HSANs) encompass a group of gene

72 of gene mutations of hereditary sensory and autonomic neuropathies I, III and IV could lead to more

73 he gene mutations for hereditary sensory and autonomic neuropathies I, III, and IV are now known and

74 hemical sympathectomy in mice resulted in BM autonomic neuropathy, impaired Lin(-)cKit(+)Sca1(+) (LKS

75 he neuropathological hallmark of sympathetic autonomic neuropathy in diabetic rats, increased 9- to 1

76 opathologic hallmark of diabetic sympathetic autonomic neuropathy in human and several insulinopenic

77 Diabetes is the most common cause of autonomic neuropathy in more developed countries.

78 neuritic dystrophy, the hallmark of diabetic autonomic neuropathy in mouse prevertebral sympathetic g

79 In conclusion, autonomic neuropathy in the BM impairs stem cell mobiliz

80 t an exclusively autoimmune pathogenesis for autonomic neuropathy in this model.

81 Autonomic neuropathy is a major component of familial am

82 Idiopathic autonomic neuropathy is a severe, subacute disorder with

83 Our findings indicate autonomic neuropathy is an early and prominent deficit i

84 Diabetic autonomic neuropathy is associated with an impaired vaso

85 Autonomic neuropathy is generally believed to be respons

86 nal degeneration characteristic for diabetic autonomic neuropathy is minor.

87 Although autonomic neuropathy is recognized as an independent ris

88 pathetic nerve fibres in human patients when autonomic neuropathy is suspected.

89 A limited autonomic neuropathy may underlie some unusual clinical

90 ility (AGID) is a limited form of autoimmune autonomic neuropathy occurring idiopathically or in a pa

91 patients with liver disease had evidence of autonomic neuropathy; of these, 12 (36%) had evidence of

92 haracterised by a progressive peripheral and autonomic neuropathy often with associated cardiac failu

93 hey are elevated, such as hereditary sensory autonomic neuropathies or diabetes.

94 elation was observed between the severity of autonomic neuropathy or the duration of diabetes and the

95 Autonomic neuropathy predisposes patients to ventricular

96 Diabetic autonomic neuropathy results in significant morbidity an

97 a (FD), a devastating hereditary sensory and autonomic neuropathy, results from an intronic mutation

98 ng cholinergic systems, including autoimmune autonomic neuropathy, seizures, dementia, and movement d

99 king improvement in the severity of diabetic autonomic neuropathy shown with IGF-I treatment in these

100 inflammation, advanced glycation endpoints, autonomic neuropathy, sleep-disordered breathing, and ge

101 ptoms were more prominent than were motor or autonomic neuropathy symptoms.

102 much greater risk of developing a painful or autonomic neuropathy than those individuals with no chan

103 It is indistinguishable from the subacute autonomic neuropathy that may accompany lung cancer or o

104 ith idiopathic and paraneoplastic autoimmune autonomic neuropathy, the severity parallels serum level

105 f a larger disease process, such as diabetic autonomic neuropathy, traumatic brain injury, and spinal

106 Hereditary sensory and autonomic neuropathy type 1 (HSAN1) causes sensory loss

107 Hereditary sensory and autonomic neuropathy type 1 (HSAN1) is characterized by

108 concentrations cause hereditary sensory and autonomic neuropathy type 1 (HSAN1), an axonal neuropath

109 (SPTLC1), which cause hereditary sensory and autonomic neuropathy type 1 (HSAN1).

110 mic the mutations seen in hereditary sensory autonomic neuropathy type 1 as well as a third mutant N1

111 ations in human SPT cause hereditary sensory autonomic neuropathy type 1, a disease characterized by

112 clinical spectrum for hereditary sensory and autonomic neuropathy type 1E (HSAN1E) and a potential pa

113 Hereditary sensory and autonomic neuropathy type I (HSAN I) is the most frequen

114 ause an adult-onset, hereditary sensory, and autonomic neuropathy type I (HSAN1).

115 ical disease known as hereditary sensory and autonomic neuropathy type I (HSAN1).

116 amilial dysautonomia (hereditary sensory and autonomic neuropathy type III), we found that the techni

117 Hereditary sensory and autonomic neuropathy type III, or familial dysautonomia

118 tions in SPTLC1 cause hereditary sensory and autonomic neuropathy (type I) (HSAN1), an adult onset, a

119 our hypothesis, we evaluated the presence of autonomic neuropathy using a battery of tests in 33 pati

120 an in vivo streptozotocin model of diabetic autonomic neuropathy using an unbiased counting method t

121 wth factor I (IGF-I) on diabetic sympathetic autonomic neuropathy was examined in an experimental str

122 ensorimotor) neuropathy was found in 71% and autonomic neuropathy was found in 48% of the patients.

123 A diagnosis of idiopathic autonomic neuropathy was made.

124 To address the pathogenesis of diabetic autonomic neuropathy, we have examined the sympathetic n

125 nly dangerous as contributors to sensory and autonomic neuropathies when elevated by inherited SPT mu

126 subsequently were found to have sensorimotor autonomic neuropathy, whereas 2 others had subclinical a

127 he areas of diabetic amyotrophy and diabetic autonomic neuropathy will also be reviewed.

128 There are several familial autonomic neuropathies with autosomal dominant, autosoma

129 tion are likely to have a high prevalence of autonomic neuropathy with an associated increase in mort

130 al dominant diseases: hereditary sensory and autonomic neuropathy with dementia and hearing loss type

131 ration in one form of hereditary sensory and autonomic neuropathy with dementia and hearing loss.

132 This is the first report of an acute autonomic neuropathy with documented EBV infection in CS

133 be a valuable model of diabetic sympathetic autonomic neuropathy with unambiguous, rapidly developin